Humacyte, Inc.: Form 10-K/A for the period ended Dec 31, 2020
Filed with the SEC on May 14, 2021 and accepted by EDGAR at May 14, 2021, 20:04 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 6 months2020-07-01 to 2020-12-31 | −$249.5k | us-gaap:OperatingIncomeLoss |
| Net income | 6 months2020-07-01 to 2020-12-31 | $1.4m | us-gaap:NetIncomeLoss |
| Operating cash flow | 6 months2020-07-01 to 2020-12-31 | −$245.7k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2020-12-31 | $1.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-12-31 | $1.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-12-31 | $101.3m | us-gaap:Assets |
| Current liabilities | At period end2020-12-31 | $247.9k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-12-31 | $8.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-12-31 | $5.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-21-026404. Last ingested by Listed: Oct 24, 2026, 15:06 ET. Listed shows no prices and gives no investment advice.